2. Signaling Pathways
  3. Immunology/Inflammation
  4. Kallikrein
  5. Kallikrein Inhibitor

Kallikrein Inhibitor

Kallikrein Inhibitors (19):

Cat. No. Product Name Effect Purity
  • HY-16735
    Avoralstat
    		Inhibitor ≥98.0%
    Avoralstat (BCX4161), a potent and orally active plasma kallikrein (PKK) inhibitor, is used for hereditary angioedema research.
  • HY-109127A
    Berotralstat dihydrochloride
    		Inhibitor 98.49%
    Berotralstat dihydrochloride is a low toxicity, effective, highly specific, second-generation, synthetic and orally active plasma kallikrein inhibitor used for the research of hereditary angioedema (HAE) attacks. Berotralstat dihydrochloride works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE.
  • HY-132830
    Sebetralstat
    		Inhibitor
    Sebetralstat (KVD900) is a plasma kallikrein inhibitor (WO2016083820). Sebetralstat can be used for the research of metabolic diseases.
  • HY-109127
    Berotralstat
    		Inhibitor 99.70%
    Berotralstat (BCX7353) is a low toxicity, effective, highly specific, second-generation, synthetic and orally active plasma kallikrein inhibitor used for the research of hereditary angioedema (HAE) attacks. Berotralstat works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE.
  • HY-P99110
    Lanadelumab
    		Inhibitor 99.57%
    Lanadelumab (SHP643) is a human IgG1 monoclonal antibody against plasma kallikrein (pKal) with an Ki value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema.
  • HY-19101
    ONO-3307
    		Inhibitor
    ONO-3307 is a protease inhibitor that competitively inhibits a variety of proteases including trypsin, thrombin, plasma kallikrein, plasmin, pancreatic kallikrein, and chymotrypsin. ONO-3307 alleviates endotoxin-induced experimental disseminated intravascular coagulation (DIC) in rats. ONO-3307 can be used in the study of thrombosis and protease-mediated diseases.
  • HY-163464
    Plasma kallikrein-IN-5
    		Inhibitor
    Plasma kallikrein-IN-5 (Compound 20) is a potent covalent inhibitor of plasma potassium kinin peptide (Pka) with IC50 values of 66 nM and 70 pM at 1 minute and 24 hours, respectively. Plasma kallikrein-IN-5 can be used IN the study of hereditary angioedema (HAE).
  • HY-123133
    PKSI-527
    		Inhibitor 98.08%
    PKSI-527 is a new, highly selective plasma kallikrein inhibitor. PKSI-527 can suppress collagen-induced arthritis (CIA) by modifying the kallikrein-kinin system.
  • HY-108814A
    Ecallantide TFA
    		Inhibitor 98.63%
    Ecallantide (DX-88) TFA is a specific recombinant plasma kallikrein inhibitor. Ecallantide inhibits the production of bradykinin. Ecallantide may be used to prevent acute attacks of angioedema.
  • HY-P4245
    D-Pro-Phe-Arg-Chloromethylketone
    		Inhibitor 98.95%
    D-Pro-Phe-Arg-Chloromethylketone, a inhibitor of coagulation factor XII and plasma kallikrein, plays an important role in thrombosis and inflammation.
  • HY-145568
    Feniralstat
    		Inhibitor 99.87%
    Feniralstat (compound 30), a pyrazole derivative, is a potent kallikrein inhibitor with an IC50 of 6.7 nM for Human plasma kallikrein (pKal). Feniralstat has no inhibition on Human KLKl, Human FXIa, Human Factor Xlla (all IC50>40 μM).
  • HY-122543
    PPACK II diTFA
    		Inhibitor
    PPACK II diTFA is an irreversible and specific glandular and plasma kallikreins inhibitor.
  • HY-126378
    LSP-249
    		Inhibitor 99.98%
    LSP-249 (example 35), extracted from patent WO2016011209A1, is a plasma kallikrein inhibitor under the study for angioedema, with an EC50 less than 100 nM in cell.
  • HY-153115
    Plasma kallikrein-IN-4
    		Inhibitor 98.61%
    Plasma kallikrein-IN-4 (Example 153) is a plasma kallikrein inhibitor with an IC50 of 0.016 μM against human plasma kallikrein.
  • HY-139888
    Plasma kallikrein-IN-1
    		Inhibitor
    Plasma kallikrein-IN-1 is a PKK inhibitor with an IC50 value of 0.5 nM.
  • HY-108814
    Ecallantide
    		Inhibitor
    Ecallantide (DX-88) is a specific plasma kallikrein inhibitor. Ecallantide inhibits the production of bradykinin. Ecallantide can be used to prevent acute attacks of angioedema.
  • HY-122543A
    PPACK II
    		Inhibitor
    PPACK II is an irreversible and specific glandular and plasma kallikreins inhibitor.
  • HY-143476
    Plasma kallikrein-IN-2
    		Inhibitor
    Plasma kallikrein-IN-2 (Compound 198) is a potent plasma kallikrein (PKal) inhibitor with an IC50 of 0.1 nM. Plasma kallikrein-IN-2 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research.
  • HY-150052
    Plasma kallikrein-IN-3
    		Inhibitor
    Plasma kallikrein-IN-3 is a plasma kallikrein inhibitor (IC50: 0.15 μM). Plasma kallikrein-IN-3 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research.